Non-surgical treatment trial for patients diagnosed with multi-vessel coronary artery disease

Study ID: HYBRID

HYBRID: Hybrid coronary revascularization trial

The purpose of the non-surgical study is to learn which treatment option is better for patients who have multi-vessel coronary artery disease, i.e., blockages in more than one vessel supplying blood to the heart muscle.

The treatment options this study will compare are as follows:

  1. Hybrid Coronary Revascularization (HCR), which is a combination of surgery and catheter procedures to open clogged heart arteries
  2. Percutaneous Coronary Intervention (PCI), a catheter procedure to open clogged heart arteries.

There are no new or experimental procedures being tested in this study—both HCR and PCI are well-established procedures and are regularly performed in patients who have coronary artery disease. However, the FDA has not yet approved the drug-eluting stents used in PCI for all types of coronary artery disease. The researchers are studying the use of the drug-eluting stents in this trial in the same way they are used in clinical practice.

The overall objective of this trial is to evaluate the effectiveness and safety of hybrid coronary revascularization (HCR) compared to multi–vessel PCI with metallic drug-eluting stents (DES) in patients with multi-vessel coronary artery disease involving the left main and/or left anterior descending arteries.

Inclusion Snapshot

Must have been diagnosed with multi-vessel coronary artery disease involving the left main and/or left anterior descending arteries

Contact Information

Lankenau Institute for Medical Research trial

Physician Investigator(s)

Study Locations